|
rs11545566
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariate analyses demonstrated that donor rs11545566 non-AA genotypes showed a trend toward a higher incidence of grade II-IV acute GVHD (P = 0.079), and were significantly associated with a higher incidence of extensive chronic GVHD (P = 0.021).
|
31559562 |
2020 |
|
rs121912651
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, the detection of pathogenic variants, including single nucleotide substitution of TP53 (c.346C>T) and BRCA2 (c.6952C>T) and splicing of KDM6A (c.1194+2T>G), suggest that the development of ESCC in the patient was triggered by impairment of checkpoint and repair for DNA damage and epigenetic modification through accumulation of gene mutations induced by chronic graft-versus-host disease and prolonged administration of tacrolimus.
|
30499911 |
2018 |
|
rs2278293
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Recipient IMPDH1 rs2278293 genotype was associated with a lower incidence of chronic GVHD (hazard ratio, .72; P = .008) in nonmyeloablative HCT recipients.
|
29656138 |
2018 |
|
rs80358920
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, the detection of pathogenic variants, including single nucleotide substitution of TP53 (c.346C>T) and BRCA2 (c.6952C>T) and splicing of KDM6A (c.1194+2T>G), suggest that the development of ESCC in the patient was triggered by impairment of checkpoint and repair for DNA damage and epigenetic modification through accumulation of gene mutations induced by chronic graft-versus-host disease and prolonged administration of tacrolimus.
|
30499911 |
2018 |
|
rs7588571
|
|
|
0.010 |
GeneticVariation |
BEFREE |
High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype.
|
28945764 |
2017 |
|
rs4553808
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We tested the hypothesis that SNP rs4553808 is associated with RFS, OS, nonrelapse mortality (NRM) and the cumulative incidence of acute graft-versus-host disease (GVHD) and chronic GVHD</span> in adults with acute myeloid leukemia and advanced myelodysplastic syndrome undergoing a first 8/8 or 7/8 HLA-matched unrelated donor HSCT.
|
24631737 |
2014 |
|
rs1131012
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We evaluated the association of 4 SNPs in ICAM1 (rs5498), PECAM1 (rs668 and rs1131012) and SELL (rs2229569) genes with acute and chronic graft-versus-host disease (GvHD) and those experiencing transplant-related mortality (TRM) within 1 year among 425 allogeneic HCT recipient-donor pairs.
|
22646485 |
2013 |
|
rs2229569
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We evaluated the association of 4 SNPs in ICAM1 (rs5498), PECAM1 (rs668 and rs1131012) and SELL (rs2229569) genes with acute and chronic graft-versus-host disease (GvHD) and those experiencing transplant-related mortality (TRM) within 1 year among 425 allogeneic HCT recipient-donor pairs.
|
22646485 |
2013 |
|
rs5498
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We evaluated the association of 4 SNPs in ICAM1 (rs5498), PECAM1 (rs668 and rs1131012) and SELL (rs2229569) genes with acute and chronic graft-versus-host disease (GvHD) and those experiencing transplant-related mortality (TRM) within 1 year among 425 allogeneic HCT recipient-donor pairs.
|
22646485 |
2013 |
|
rs668
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We evaluated the association of 4 SNPs in ICAM1 (rs5498), PECAM1 (rs668 and rs1131012) and SELL (rs2229569) genes with acute and chronic graft-versus-host disease (GvHD) and those experiencing transplant-related mortality (TRM) within 1 year among 425 allogeneic HCT recipient-donor pairs.
|
22646485 |
2013 |
|
rs12428930
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In multivariate analyses, 4 recipient BAFF SNPs (rs16972217 [odds ratio = 2.72, P = .004], rs7993590 [odds ratio = 2.35, P = .011], rs12428930 [odds ratio2.53, P = .008], and rs2893321 [odds ratio = 2.48, P = .009]) were independent predictors of GVHD subtypes, adjusted for conventional predictors of cGVHD.
|
21628416 |
2011 |
|
rs16972217
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In multivariate analyses, 4 recipient BAFF SNPs (rs16972217 [odds ratio = 2.72, P = .004], rs7993590 [odds ratio = 2.35, P = .011], rs12428930 [odds ratio2.53, P = .008], and rs2893321 [odds ratio = 2.48, P = .009]) were independent predictors of GVHD subtypes, adjusted for conventional predictors of cGVHD.
|
21628416 |
2011 |
|
rs2301436
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In multivariate analysis, patients receiving a transplant from a homozygous rs2301436 G allele donor showed less cGVHD (odds ratio [OR]: 0.16; P = .002), as was the case for a homozygous donor rs3093023 G allele (OR: 0.24; P = .005).
|
21763254 |
2011 |
|
rs2893321
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In multivariate analyses, 4 recipient BAFF SNPs (rs16972217 [odds ratio = 2.72, P = .004], rs7993590 [odds ratio = 2.35, P = .011], rs12428930 [odds ratio2.53, P = .008], and rs2893321 [odds ratio = 2.48, P = .009]) were independent predictors of GVHD subtypes, adjusted for conventional predictors of cGVHD.
|
21628416 |
2011 |
|
rs3093023
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In multivariate analysis, patients receiving a transplant from a homozygous rs2301436 G allele donor showed less cGVHD (odds ratio [OR]: 0.16; P = .002), as was the case for a homozygous donor rs3093023 G allele (OR: 0.24; P = .005).
|
21763254 |
2011 |
|
rs7993590
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In multivariate analyses, 4 recipient BAFF SNPs (rs16972217 [odds ratio = 2.72, P = .004], rs7993590 [odds ratio = 2.35, P = .011], rs12428930 [odds ratio2.53, P = .008], and rs2893321 [odds ratio = 2.48, P = .009]) were independent predictors of GVHD subtypes, adjusted for conventional predictors of cGVHD.
|
21628416 |
2011 |
|
rs1805410
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One SNP in PARP1 gene (rs1805410) was associated with a higher risk of chronic GVHD (RR: 1.81, 95% CI: 1.29-2.54, P=0.001).
|
20574454 |
2010 |